249 related articles for article (PubMed ID: 18193917)
41. The pharmacokinetics or oral and intravenous allopurinol and intravenous oxypurinol in the horse.
Mills PC; Dunnett M; Smith NC
J Vet Pharmacol Ther; 1995 Dec; 18(6):451-6. PubMed ID: 8789699
[TBL] [Abstract][Full Text] [Related]
42. Effects of bovine milk ingestion on urinary excretion of oxypurinol and uric acid.
Kurajoh M; Ka T; Okuda C; Yamamoto A; Tsutsumi Z; Koyama H; Moriwaki Y; Yamamoto T
Int J Clin Pharmacol Ther; 2011 Jun; 49(6):366-70. PubMed ID: 21612743
[TBL] [Abstract][Full Text] [Related]
43. Disposition and uric acid lowering effect of oxipurinol: comparison of different oxipurinol formulations and allopurinol in healthy individuals.
Walter-Sack I; de Vries JX; Kutschker C; Ittensohn A; Voss A
Eur J Clin Pharmacol; 1995; 49(3):215-20. PubMed ID: 8665998
[TBL] [Abstract][Full Text] [Related]
44. Difference of the plasma concentration and urinary excretion of allopurinol, oxypurinol, and purine bases between dietary intake and fasting.
Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Yamakita J; Higashino K
Int J Clin Pharmacol Ther; 1996 Apr; 34(4):157-62. PubMed ID: 8861734
[TBL] [Abstract][Full Text] [Related]
45. Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia.
Stamp LK; Turner R; Khalilova IS; Zhang M; Drake J; Forbes LV; Kettle AJ
Rheumatology (Oxford); 2014 Nov; 53(11):1958-65. PubMed ID: 24899662
[TBL] [Abstract][Full Text] [Related]
46. [Clinical pharmacokinetics of allopurinol. 3. Allopurinol/oxipurinol pharmacokinetics following administration of a controlled release allopurinol preparation].
Gikalov I; Radivojevich F; Schiemann O; Fenner H
Arzneimittelforschung; 1986 Jun; 36(6):988-93. PubMed ID: 3741536
[TBL] [Abstract][Full Text] [Related]
47. Molecular mechanism of an adverse drug-drug interaction of allopurinol and furosemide in gout treatment.
Knake C; Stamp L; Bahn A
Biochem Biophys Res Commun; 2014 Sep; 452(1):157-62. PubMed ID: 25152400
[TBL] [Abstract][Full Text] [Related]
48. Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia.
Wen YF; Brundage RC; Roman YM; Culhane-Pera KA; Straka RJ
Br J Clin Pharmacol; 2023 Oct; 89(10):2964-2976. PubMed ID: 37202871
[TBL] [Abstract][Full Text] [Related]
49. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
[TBL] [Abstract][Full Text] [Related]
50. A simple method for quantification of allopurinol and oxipurinol in human serum by high-performance liquid chromatography with UV-detection.
Reinders MK; Nijdam LC; van Roon EN; Movig KL; Jansen TL; van de Laar MA; Brouwers JR
J Pharm Biomed Anal; 2007 Oct; 45(2):312-7. PubMed ID: 17890037
[TBL] [Abstract][Full Text] [Related]
51. Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study.
Fleischmann R; Winkle P; Miner JN; Yan X; Hicks L; Valdez S; Hall J; Liu S; Shen Z; Gillen M; Hernandez-Illas M
RMD Open; 2018; 4(1):e000584. PubMed ID: 29531784
[TBL] [Abstract][Full Text] [Related]
52. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects.
Ayalasomayajula S; Tchaloyan S; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
Curr Med Res Opin; 2008 Mar; 24(3):717-26. PubMed ID: 18234150
[TBL] [Abstract][Full Text] [Related]
53. Effect of furosemide on renal excretion of oxypurinol and purine bases.
Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Hada T
Metabolism; 2001 Feb; 50(2):241-5. PubMed ID: 11229436
[TBL] [Abstract][Full Text] [Related]
54. Benzbromarone therapy in hyperuricaemia; comparison with allopurinol and probenecid.
Schepers GW
J Int Med Res; 1981; 9(6):511-5. PubMed ID: 7033016
[TBL] [Abstract][Full Text] [Related]
55. Interaction of allopurinol and hydrochlorothiazide during prolonged oral administration of both drugs in normal subjects. II. Kinetics of allopurinol, oxipurinol, and hydrochlorothiazide.
de Vries JX; Voss A; Ittensohn A; Walter-Sack I; Löffler W; Landthaler R; Zöllner N
Clin Investig; 1994 Dec; 72(12):1076-81. PubMed ID: 7711419
[TBL] [Abstract][Full Text] [Related]
56. Pharmacology of drugs for hyperuricemia. Mechanisms, kinetics and interactions.
Pea F
Contrib Nephrol; 2005; 147():35-46. PubMed ID: 15604604
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
[TBL] [Abstract][Full Text] [Related]
58. Allopurinol: a comparative study of the bioavailability and effect on plasma uric acid of two products in tablet form.
Nissen P; Pedersen L
Biopharm Drug Dispos; 1985; 6(4):441-6. PubMed ID: 4084669
[TBL] [Abstract][Full Text] [Related]
59. [The clinical pharmacokinetics of allopurinol. 2. Allopurinol/oxypurinol pharmacokinetics following allopurinol in single doses and multiple application].
Fenner H; Schiemann O; Gikalov I
Arzneimittelforschung; 1985; 35(7):1093-6. PubMed ID: 4052144
[TBL] [Abstract][Full Text] [Related]
60. Placental transfer and pharmacokinetics of allopurinol in late pregnant sows and their fetuses.
van Dijk AJ; Parvizi N; Taverne MA; Fink-Gremmels J
J Vet Pharmacol Ther; 2008 Dec; 31(6):489-95. PubMed ID: 19000269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
